Investigational drug · Phase 3
AK3280
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Idiopathic Pulmonary Fibrosis (IPF).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "AK3280"
First trial start
2026
Aug 31, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AK3280", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "AK3280" as an intervention, largest first.
- A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingNot yet recruiting
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT07719023 · 263 participants (planned) · Start Aug 31, 2026 · Primary completion Sep 30, 2028
Drug: AK3280; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisPivotal-lookingStatus unknown
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT05424887 · 105 participants (planned) · Start Jul 2022 · Primary completion Jul 2024
Drug: AK3280; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT03990688 · 48 participants · Start Oct 3, 2019 · Primary completion Sep 9, 2020
Drug: AK3280; Placebo · For: Healthy
Sites: Uppsala, Sweden
- A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic ScarCompleted
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT05434897 · 30 participants · Start Jul 8, 2022 · Primary completion Jul 18, 2023
Drug: AK3280 Cream; Placebo cream · For: Hypertrophic Scar
Sites: Shanghai, China
Shanghai Ark Biopharmaceutical Co., Ltd.Industry
NCT04926116 · 24 participants · Start Jun 9, 2021 · Primary completion Sep 28, 2021
Drug: AK3280; Placebo · For: Healthy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models.
Gao Z, Cao S, Yuan H, et al. · Int Immunopharmacol 2025
Also in development for Idiopathic Pulmonary Fibrosis (IPF)
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- HEC585Phase 33 trials
Sunshine Lake Pharma Co., Ltd. · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- DeupirfenidonePhase 32 trials
PureTech · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- INS018_055Phase 32 trials
InSilico Medicine Hong Kong Limited · Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
- TDI01Phase 32 trials
Beijing Tide Pharmaceutical Co., Ltd · GVHD, Chronic, Idiopathic Pulmonary Fibrosis (IPF)
- HB0056Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Asthma, Idiopathic Pulmonary Fibrosis (IPF)
- AGMB-447Phase 21 trial
Agomab Spain S.L.U. · Idiopathic Pulmonary Fibrosis (IPF)
- AP02Phase 21 trial
Avalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.